Therapeutic effects of short‐ and intermediate‐term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis

Abstract

Tolvaptan safely alleviated fluid retention caused by hepatic cirrhosis. Intermediate-term administration of tolvaptan apparently helped maintain weight reduction achieved during the introduction phase.